/ Side by side
Tirzepatide vs Retatrutide
A neutral, side-by-side look at Tirzepatide and Retatrutide: what each one is, its class, half-life, storage, and the public sources behind it. Educational reference only, not medical advice, dosing, or a recommendation to use either compound.
Tirzepatide
Mounjaro · Zepbound
Full profile →Retatrutide
Reta · Triple-G · LY3437943
Full profile →| Attribute | Tirzepatide | Retatrutide |
|---|---|---|
| Category | GLP-1 / Metabolic | GLP-1 / Metabolic |
| Half-life | ~5 days | ~6 days, subcutaneous |
| Common vial | 5, 10, 15, 20, 30, 60 mg | 5, 10, 15, 20, 30 mg |
| Reference | Verified | Verified |
What is Tirzepatide?
A dual GIP and GLP-1 receptor agonist with a fatty-diacid modification for albumin binding, studied for glycemic control in type 2 diabetes and for weight management. Its half-life supports once-weekly administration.
Sources
- FDA approvals: Mounjaro (2022), Zepbound (2023)
- Schneck et al., CPT Pharmacometrics Syst Pharmacol 2024
What is Retatrutide?
An investigational triple receptor agonist (GIP, GLP-1 and glucagon) conjugated to a fatty-diacid for albumin binding, studied in trials for obesity and metabolic disease. Its half-life supports once-weekly administration.
Sources
- Jastreboff et al., NEJM 2023 (phase 2 obesity)
- Nature Medicine 2024 (phase 2a MASLD)
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.